{"denoms":[{"counts":[{"groupId":"BG000","value":"227"},{"groupId":"BG001","value":"226"},{"groupId":"BG002","value":"453"}],"units":"Participants"}],"groups":[{"description":"Participants received single-agent MIRV at 6 mg/kg AIBW administered IV on Day 1 of Q3W.","id":"BG000","title":"Mirvetuximab Soravtansine"},{"description":"Participants received a dose of IC chemotherapeutic agent calculated using BSA. Paclitaxel administered at 80 mg/m\\^2 as a 1-hour IV infusion on Days 1, 8, 15, and 22 of a 4-week cycle; or topotecan administered at 4 mg/m\\^2 over 30 minutes on Days 1, 8, and 15 of a 4-week cycle. Alternatively, topotecan could have been administered at 1.25 mg/m\\^2 over 30 minutes on Days 1 to 5 of a 3-week cycle; or pegylated liposomal doxorubicin administered at 40 mg/m\\^2 as a 1 mg/minute IV infusion on Day 1 of a 4-week cycle. After Cycle 1, if tolerated, pegylated liposomal doxorubicin could have been administered as a 1-hour infusion.","id":"BG001","title":"Investigator's Choice (IC) Chemotherapy"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.85","value":"63.3"},{"groupId":"BG001","spread":"9.30","value":"62.3"},{"groupId":"BG002","spread":"9.58","value":"62.8"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"227"},{"groupId":"BG001","value":"226"},{"groupId":"BG002","value":"453"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"27"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"177"},{"groupId":"BG001","value":"163"},{"groupId":"BG002","value":"340"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"86"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"53"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"13"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"156"},{"groupId":"BG001","value":"145"},{"groupId":"BG002","value":"301"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"51"},{"groupId":"BG002","value":"86"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"The intent-to-treat (ITT) population included all participants randomized to the study, regardless of whether or not participants received study treatment (MIRV or IC Chemo)."}